EP3727362A4 - Promédicaments lipidiques d'acide mycophénolique et leurs utilisations - Google Patents
Promédicaments lipidiques d'acide mycophénolique et leurs utilisations Download PDFInfo
- Publication number
- EP3727362A4 EP3727362A4 EP18890811.5A EP18890811A EP3727362A4 EP 3727362 A4 EP3727362 A4 EP 3727362A4 EP 18890811 A EP18890811 A EP 18890811A EP 3727362 A4 EP3727362 A4 EP 3727362A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- mycophenolic acid
- medicinal products
- acid lipid
- lipid medicinal
- products
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607749P | 2017-12-19 | 2017-12-19 | |
| US201862724274P | 2018-08-29 | 2018-08-29 | |
| US201862768583P | 2018-11-16 | 2018-11-16 | |
| PCT/US2018/066585 WO2019126378A1 (fr) | 2017-12-19 | 2018-12-19 | Promédicaments lipidiques d'acide mycophénolique et leurs utilisations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3727362A1 EP3727362A1 (fr) | 2020-10-28 |
| EP3727362A4 true EP3727362A4 (fr) | 2021-10-06 |
Family
ID=66994291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP18890811.5A Pending EP3727362A4 (fr) | 2017-12-19 | 2018-12-19 | Promédicaments lipidiques d'acide mycophénolique et leurs utilisations |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP3727362A4 (fr) |
| WO (1) | WO2019126378A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019046491A1 (fr) | 2017-08-29 | 2019-03-07 | Ariya Therapeutics, Inc. | Promédicaments lipidiques orientant vers le système lymphatique |
| US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
| CN109851593B (zh) * | 2019-02-01 | 2021-04-16 | 沈阳药科大学 | 基于淋巴介导转运的甘油三酯前药及其制备方法 |
| JP7600208B2 (ja) | 2019-07-29 | 2024-12-16 | ジョージア テック リサーチ コーポレイション | 拘束された脂質を含むナノ材料およびその使用 |
| AU2020396940A1 (en) * | 2019-12-06 | 2022-06-16 | Guide Therapeutics, Llc | Nanomaterials |
| WO2021141969A1 (fr) | 2020-01-09 | 2021-07-15 | Guide Therapeutics, Inc. | Nanomatériaux |
| MX2023008328A (es) | 2021-01-20 | 2023-08-15 | Beam Therapeutics Inc | Nanomateriales que comprenden una caracteristica biodegradable. |
| AU2023311822A1 (en) | 2022-07-20 | 2025-01-09 | Beam Therapeutics Inc. | Nanomaterials comprising triols |
| CN120983421A (zh) * | 2025-09-08 | 2025-11-21 | 齐鲁工业大学(山东省科学院) | 霉酚酸甲酯在制备抗血栓药物中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017041139A1 (fr) * | 2015-09-08 | 2017-03-16 | Monash University | Promédicaments ciblant la lymphe |
| WO2019046491A1 (fr) * | 2017-08-29 | 2019-03-07 | Ariya Therapeutics, Inc. | Promédicaments lipidiques orientant vers le système lymphatique |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013665A (en) | 1997-12-16 | 2000-01-11 | Abbott Laboratories | Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides |
| US7071189B2 (en) | 2001-04-27 | 2006-07-04 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| WO2004019973A1 (fr) | 2002-08-14 | 2004-03-11 | Atugen Ag | Nouvelle mise en application de la proteine kinase n beta |
| JP2006523237A (ja) | 2003-04-03 | 2006-10-12 | セマフォア ファーマシューティカルズ, インコーポレイテッド | Pi−3キナーゼインヒビタープロドラッグ |
| US7425553B2 (en) | 2003-05-30 | 2008-09-16 | Gemin X Pharmaceuticals Canada Inc. | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| CA2531069A1 (fr) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition de l'expression d'une syk kinase |
| EP1761540B1 (fr) | 2004-05-13 | 2016-09-28 | Icos Corporation | Quinazolinones utilisees en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase delta humaine |
| JP4801096B2 (ja) | 2005-01-19 | 2011-10-26 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用 |
| EP2757099B1 (fr) | 2005-05-12 | 2017-08-23 | AbbVie Bahamas Limited | Promoteurs d'apoptose |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| AU2006302179C1 (en) | 2005-10-07 | 2013-06-20 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| US7528143B2 (en) | 2005-11-01 | 2009-05-05 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| CN103214484B (zh) | 2005-12-13 | 2016-07-06 | 因塞特控股公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| BRPI0707739A2 (pt) * | 2006-02-13 | 2011-05-10 | Novartis Ag | dosagem elevada de Ácido micofenàlico |
| RU2439074C2 (ru) | 2006-04-26 | 2012-01-10 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К) |
| US8236788B2 (en) | 2006-07-24 | 2012-08-07 | Basf Se | Azolylmethyloxiranes, use thereof for controlling plant pathogenic fungi, and agents containing the same |
| PL2526933T3 (pl) | 2006-09-22 | 2015-08-31 | Pharmacyclics Llc | Inhibitory kinazy tyrozynowej Brutona |
| US8486941B2 (en) | 2007-03-12 | 2013-07-16 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| KR100975520B1 (ko) | 2008-02-01 | 2010-08-12 | 종근당바이오 주식회사 | 마이코페놀레이트 모페틸의 개선된 제조방법 |
| TWI444382B (zh) | 2008-03-11 | 2014-07-11 | Incyte Corp | 作為jak抑制劑之氮雜環丁烷及環丁烷衍生物 |
| JP5757864B2 (ja) | 2008-05-20 | 2015-08-05 | ニューロジェシックス, インコーポレイテッド | 水溶性アセトアミノフェン類似体 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| WO2011051967A2 (fr) * | 2009-10-23 | 2011-05-05 | Alkem Laboratories Ltd | Compositions pharmaceutiques contenant du mycophénolate et leurs procédés de préparation |
| US20110213028A1 (en) * | 2010-02-26 | 2011-09-01 | Catabasis Pharmaceuticals, Inc. | Fatty acid mycophenolate derivatives and their uses |
| CN117164657A (zh) * | 2014-08-12 | 2023-12-05 | 莫纳什大学 | 定向淋巴的前药 |
-
2018
- 2018-12-19 WO PCT/US2018/066585 patent/WO2019126378A1/fr not_active Ceased
- 2018-12-19 EP EP18890811.5A patent/EP3727362A4/fr active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017041139A1 (fr) * | 2015-09-08 | 2017-03-16 | Monash University | Promédicaments ciblant la lymphe |
| WO2019046491A1 (fr) * | 2017-08-29 | 2019-03-07 | Ariya Therapeutics, Inc. | Promédicaments lipidiques orientant vers le système lymphatique |
| EP3675838A1 (fr) * | 2017-08-29 | 2020-07-08 | Puretecch LYT, Inc. | Promédicaments lipidiques orientant vers le système lymphatique |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2019126378A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019126378A1 (fr) | 2019-06-27 |
| EP3727362A1 (fr) | 2020-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3478693A4 (fr) | Dérivés d'acide boronique et leurs utilisations thérapeutiques | |
| MA53650A (fr) | Lipides peg et leurs utilisations | |
| MA53652A (fr) | Lipides peg de haute pureté et leurs utilisations | |
| EP3817769A4 (fr) | Anticorps anti-cd47 humains et leurs utilisations | |
| EP3891183A4 (fr) | Anticorps anti-claudine et leurs utilisations | |
| EP3759143A4 (fr) | Anticorps anti-tigit et leurs utilisations | |
| EP3625263A4 (fr) | Anticorps anti-galectine-9 et leurs utilisations | |
| EP3720502A4 (fr) | Produits cytobiologiques et leurs utilisations thérapeutiques | |
| EP3370770A4 (fr) | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations | |
| MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
| EP3481430A4 (fr) | Conjugués de type acide nucléique et leurs utilisations | |
| EP3475449A4 (fr) | Étalons d'acide nucléique acellulaire et leurs utilisations | |
| EP3518971A4 (fr) | Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations | |
| MA44955A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
| MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
| EP2946015A4 (fr) | Complexes d'acide nucléique cas9 et leurs utilisations | |
| EP3681912A4 (fr) | Anticorps spécifiques d'axl et leurs utilisations | |
| EP3555076A4 (fr) | Nouveaux dérivés de l'acide phényl propionique et leurs utilisations | |
| EP3645563A4 (fr) | Anticorps anti-fam19a5 et leurs utilisations | |
| EP3790586A4 (fr) | Anticorps anti-dll3 et leurs utilisations | |
| EP3672987A4 (fr) | Anticorps anti-apéline et leurs utilisations | |
| EP3380525A4 (fr) | Formulations pharmaceutiques et leurs procédés d'utilisation | |
| EP3850012A4 (fr) | Anticorps anti-tnfrsf9 et leurs utilisations | |
| EP3755714A4 (fr) | Anticorps anti-angiopoïétine-2 et leurs utilisations | |
| MA54469A (fr) | Anticorps anti-il-27 et leurs utilisations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20200717 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20210902 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20220614 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031138000 Ipc: A61K0045060000 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0045060000 Ipc: A61K0047540000 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 307/88 20060101ALI20241009BHEP Ipc: A61K 47/54 20170101ALI20241009BHEP Ipc: A61K 45/06 20060101AFI20241009BHEP |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 19/02 20060101ALI20241011BHEP Ipc: A61P 25/00 20060101ALI20241011BHEP Ipc: A61P 1/00 20060101ALI20241011BHEP Ipc: A61P 37/06 20060101ALI20241011BHEP Ipc: A61P 37/00 20060101ALI20241011BHEP Ipc: C07D 307/88 20060101ALI20241011BHEP Ipc: A61K 45/06 20060101ALI20241011BHEP Ipc: A61K 47/54 20170101AFI20241011BHEP |
|
| INTG | Intention to grant announced |
Effective date: 20241029 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MONASH UNIVERSITY Owner name: SEAPORT THERAPEUTICS, INC. |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTC | Intention to grant announced (deleted) | ||
| RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MONASH UNIVERSITY Owner name: SEAPORT THERAPEUTICS, INC. |
|
| INTG | Intention to grant announced |
Effective date: 20250318 |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTC | Intention to grant announced (deleted) | ||
| INTG | Intention to grant announced |
Effective date: 20250804 |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| INTC | Intention to grant announced (deleted) | ||
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20260129 |